- Home
- MDAI vs KLRS Comparison
MDAI vs KLRS Comparison
Compare MDAI & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- KLRS
- Stock Information
- Founded
- MDAI 2013
- KLRS 2019
- Country
- MDAI United States
- KLRS United States
- Employees
- MDAI N/A
- KLRS N/A
- Industry
- MDAI Medical/Dental Instruments
- KLRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDAI Health Care
- KLRS Health Care
- Exchange
- MDAI Nasdaq
- KLRS Nasdaq
- Market Cap
- MDAI 51.9M
- KLRS 46.0M
- IPO Year
- MDAI N/A
- KLRS N/A
- Fundamental
- Price
- MDAI $2.21
- KLRS $4.39
- Analyst Decision
- MDAI Strong Buy
- KLRS Strong Buy
- Analyst Count
- MDAI 1
- KLRS 2
- Target Price
- MDAI $3.50
- KLRS $23.00
- AVG Volume (30 Days)
- MDAI 293.8K
- KLRS 728.6K
- Earning Date
- MDAI 11-05-2025
- KLRS 11-15-2025
- Dividend Yield
- MDAI N/A
- KLRS N/A
- EPS Growth
- MDAI N/A
- KLRS N/A
- EPS
- MDAI N/A
- KLRS N/A
- Revenue
- MDAI $27,549,000.00
- KLRS N/A
- Revenue This Year
- MDAI N/A
- KLRS N/A
- Revenue Next Year
- MDAI $60.05
- KLRS N/A
- P/E Ratio
- MDAI N/A
- KLRS N/A
- Revenue Growth
- MDAI 22.27
- KLRS N/A
- 52 Week Low
- MDAI $0.82
- KLRS $2.14
- 52 Week High
- MDAI $3.25
- KLRS $24.15
- Technical
- Relative Strength Index (RSI)
- MDAI 59.75
- KLRS 58.92
- Support Level
- MDAI $1.78
- KLRS $3.49
- Resistance Level
- MDAI $2.02
- KLRS $5.30
- Average True Range (ATR)
- MDAI 0.10
- KLRS 0.77
- MACD
- MDAI 0.05
- KLRS -0.01
- Stochastic Oscillator
- MDAI 93.48
- KLRS 23.97
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About KLRS Kalaris Therapeutics Inc. Common Stock
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.